Expert Interview
A Second Look: Understanding the potential of two drugs: SNDX-5613 (revumenib) by Syndax Pharma and Ziftomenib by Kura Oncology, both being developed for treating Acute Myeloid Leukemia with recent data released at the 2022 ASH Conference.
Ticker(s): SNDX, KURAInstitution: Arizona Oncology Associates
- Oncologist with over 25 years practicing general oncology
- Previously served as Clinical Associate Professor of Medicine at the University of Arizona and was a principal investigator at the Colorado Cancer Research Program.
- Has co-authored multiple papers on the topics of leukemia, colon cancer, and breast cancer which have been published in multiple journals including The Journal of Clinical Oncology.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
